Litifilimab (anti-CLEC4C) - Anticorpo primário, specific to CLEC4C, Human IgG1, INHIBITOR of C-type lectin domain family 4 member C inhibitor, INHIBITOR of C-type lectin domain family 4 member C inhibitor

CAS: 2407378-48-5 Cat. No.: Ab182759

GRADE & PURITY Animal Free, RUO, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Application

Animal Model, ELISA, Flow Cytometry, Functional Assay

Host species

Humano

Reactive species

Humano

Isotype

Human IgG1

Conjugation

Unconjugated

Visão geral

Litifilimab (anti-CLEC4C) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab (anti-CLEC4C) can be used for cutaneous lupus erythematosus (CLE) study.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Specifications

Product Name

Litifilimab (anti-CLEC4C) - Anticorpo primário, specific to CLEC4C, Human IgG1, INHIBITOR of C-type lectin domain family 4 member C inhibitor

Sinónimos

BDCA-2 antibody | BDCA2 antibody | Blood dendritic cell antigen 2 antibody | Blood dendritic cell antigen 2 protein antibody | C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 11 antibody | C-type (calcium dependent,

Especificações e pureza

RUO, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Espécie hospedeira

Humano

Especificidade

CLEC4C

Conjugação

Unconjugated

Grau

Animal Free, RUO

Tipo de ação

INHIBITOR

Mecanismo de ação

INHIBITOR of C-type lectin domain family 4 member C inhibitor

Isótipo

Human IgG1

Tipo de corrente de luz

kappa

SDS-PAGE

28.0 kDa (Light Chain) & 50.7 kDa (Heavy Chain), under reducing conditions; 204.4 kDa, under non-reducing conditions.

Método de purificação

Protein A purified

Concentração

See COA

CAS

2407378-48-5

Armazenamento e envio

Forma

Liquid

Condições de armazenamento de armazenamento

Store at -80°C,Avoid repeated freezing and thawing

Enviado em

Dry ice packs + Cold packs

Estabilidade e armazenamento

Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Imagens

ELISA: Litifilimab (anti-CLEC4C) (Ab182759)

Litifilimab (anti-CLEC4C) (Ab182759) - ELISA
Immobilized BDCA2-ECD-his at 2.0 μg/mL can bind Litifilimab (anti-CLEC4C) (Ab182759) with the EC ₅₀ of 19.73 ng/mL.

SEC: Litifilimab (anti-CLEC4C) (Ab182759)

Litifilimab (anti-CLEC4C) (Ab182759) - SEC
The purity of Litifilimab (anti-CLEC4C) (Ab182759) is more than 95% verified by HPLC.

Alvos associados (humanos)

CLEC4C Tbio C-type lectin domain family 4 member C (0 Activities)

Discover Target: CLEC4C

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mecanismos de ação